NAT10 and neoplasm: In vivo study, the subcutaneous tumor-forming assay was used in nude mice to detect the changes in the subcutaneous tumor-forming ability of HCC cells after NAT10 inhibition, and the changes in metastasis ability of HCC cells and the efficacy of lenvatinib after NAT10 downregulation.